TSS
NVCR icon

Two Sigma Securities’s NovoCure NVCR Stock Holding History

Two Sigma Securities’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,852
Closed -$270K – 2023
2025
Q4 		$270K Buy
+20,852
New +$268K 0.04% 684
2024
Q3 		– Sell
-22,721
Closed -$389K – 3403
2024
Q2 		$389K Sell
22,721
-7,472
-25% -$131K ﹤0.01% 1758
2024
Q1 		$472K Sell
30,193
-14,365
-32% -$211K ﹤0.01% 1622
2023
Q4 		$665K Buy
44,558
+24,917
+127% +$333K 0.01% 1336
2023
Q3 		$317K Buy
+19,641
New +$566K ﹤0.01% 1907
2022
Q2 		– Sell
-13,461
Closed -$1.11M – 2661
2022
Q1 		$1.11M Buy
+13,461
New +$992K 0.04% 564
2020
Q1 		– Sell
-9,435
Closed -$795K – 2011
2019
Q4 		$795K Buy
+9,435
New +$762K 0.01% 1174

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Two Sigma Securities's NVCR Position: Q1 2026 in Review

Two Sigma Securities sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 20,852 shares — an estimated $270K sold.

Two Sigma Securities first reported a position in NVCR in Q4 2019 and held it in 7 quarters. The position peaked at $1.11M in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Two Sigma Securities reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 20,852 NovoCure shares in Q1 2026, an estimated $270K.
  • Two Sigma Securities first reported a position in NovoCure in Q4 2019 and held it in 7 quarters.
  • Two Sigma Securities's NovoCure position peaked at $1.11M in Q1 2022.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.